JBIO logo

JADE BIOSCIENCES INC

JBIONASDAQ
πŸ† #2266 by market capEarnings Mar 4 Β· PostUS Equity
$15.31β–² $0.22 (+1.46%)
Market closed Β· at close
πŸ””
Track JBIO
Get earnings, price moves & breaking news on Telegram
Track
24hβ–² 1.5%
7dβ–Ό 5.3%
14dβ–² 1.6%
30dβ–² 5.0%
ytdβ–Ό 0.5%
1yβ–² 27.7%
🏦Market Cap
$974M
Small Cap
πŸ“ˆRevenue Growth (YoY)
β€”
πŸ“ŠGross Margin
β€”
πŸ’΅FCF Margin
β€”
βš–οΈP/S Ratio
β€”
Otter Score
β€”
Insufficient data

Trading Snapshot

Day Range
$15.20 – $15.50
52-Week Range
$11.02 – $28.00
Volume (shares)
67,474
Avg Volume (shares)
β€”
Shares Outstanding
63.6M
Next Earnings
2027-03-04

Fundamentals Snapshot

Annual Revenue
β€”
Last Q Revenue
β€”
P/E Ratio
β€”
P/S Ratio
β€”
EPS (TTM)
$-2.84
Dividend Yield
β€”
Dilution (1yr)
+5855.0%
JBIO logo

JADE BIOSCIENCES INC

JBIO
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
βˆ’$114Mβ–² +52.2% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
βˆ’$95Mβ–² +33.3% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
49.3Mβ–² +5855.0% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$88Mβ–² +$54M YoY
StockOtter Β· stockotter.space

About JADE BIOSCIENCES INC

Jade Biosciences, Inc. operates as a biotechnology enterprise, primarily focused on pioneering superior therapeutic solutions for significant unmet medical requirements in autoimmune disorders. Its leading development candidate, JADE-001, specifically targets the anti-A PRoliferation-Inducing Ligand (APRIL) pathway, aiming to treat immunoglobulin A (IgA) nephropathy. Clinical trials for JADE-001 are slated to commence in the latter half of 2025, with initial results projected for the first half of 2026. Beyond this lead asset, the company's robust pipeline includes two preclinical antibody programs, JADE-002 and JADE-003.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

⚑Momentumβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Insufficient data
β€”/100

Analyst Ratings

β“˜
Consensus
Buy
17 analysts
Strong Buy8
Buy8
Hold1
Sell0
Strong Sell0
Ratings as of Nov 2026

Latest News & Updates

News unavailable.